Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness
Overview
Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Diagnostic
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: April 2008
Interventions
- Drug: ipratropium bromide
- 2 puffs (40 micrograms) 2 puffs (0micrograms)
- Drug: placebo
- Matched placebo
Arms, Groups and Cohorts
- Active Comparator: 1
- Placebo Comparator: 2
Clinical Trial Outcome Measures
Primary Measures
- methacholine PC20
- Time Frame: 6hours and 12 hours post inhalation
Participating in This Clinical Trial
Inclusion Criteria
- Diagnosis of asthma; stable and controlled – FEV1 greater than or equal to 65% predicted Exclusion Criteria:
- Concomitant lung disease other than asthma
Gender Eligibility: All
Minimum Age: 19 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of Saskatchewan
- Collaborator
- Royal University Hospital Foundation
- Provider of Information About this Clinical Study
- Dr. Donald W. Cockcroft, Department of Medicine, University of Saskatchewan
- Overall Official(s)
- Donald W Cockcroft, MD, Principal Investigator, Department of Medicine University of Saskatchewan
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.